Connection

Martine Bagot to Lymphoma, T-Cell, Cutaneous

Back to Details
This is a "connection" page, showing publications Martine Bagot has written about Lymphoma, T-Cell, Cutaneous.
Martine Bagot
Connection Strength
4.741
Lymphoma, T-Cell, Cutaneous
  1. Management of primary cutaneous lymphoma patients during COVID-19 pandemic: EORTC CLTF guidelines. J Eur Acad Dermatol Venereol. 2020 08; 34(8):1633-1636.
    View in: PubMed
    Score: 0.743
  2. IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial. Lancet Oncol. 2019 08; 20(8):1160-1170.
    View in: PubMed
    Score: 0.691
  3. Severe hypercalcemia complicating granulomatous slack skin disease: an exceptional case. J Eur Acad Dermatol Venereol. 2019 10; 33(10):e354-e356.
    View in: PubMed
    Score: 0.686
  4. Updates in cutaneous lymphoma: evidence-based guidelines for the management of cutaneous lymphoma 2018. Br J Dermatol. 2019 03; 180(3):443-444.
    View in: PubMed
    Score: 0.676
  5. A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs. Eur J Dermatol. 2017 Jun 01; 27(3):286-294.
    View in: PubMed
    Score: 0.599
  6. [Granulomatous slack skin associated with metastatic testicular seminoma]. Ann Dermatol Venereol. 2017 Jun - Jul; 144(6-7):446-449.
    View in: PubMed
    Score: 0.593
  7. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018 09; 19(9):1192-1204.
    View in: PubMed
    Score: 0.163
  8. IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma. Expert Opin Investig Drugs. 2018 Aug; 27(8):691-697.
    View in: PubMed
    Score: 0.162
  9. KIR3DL2 expression in cutaneous T-cell lymphomas: expanding the spectrum for KIR3DL2 targeting. Blood. 2017 12 28; 130(26):2900-2902.
    View in: PubMed
    Score: 0.154
  10. Immediate hypersensitivity reaction to pegylated liposomal doxorubicin: management and outcome in four patients. Eur J Dermatol. 2017 Jun 01; 27(3):271-274.
    View in: PubMed
    Score: 0.150
  11. IPH4102, a humanized KIR3DL2 antibody with potent activity against cutaneous T-cell lymphoma. Cancer Res. 2014 Nov 01; 74(21):6060-70.
    View in: PubMed
    Score: 0.125
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.